WALTHAM, Mass., April 24, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG), a specialty pharmaceutical company, today reported unaudited consolidated financial results for the first quarter ended March 31, 2014. The company achieved 17% total net revenue growth in the first quarter of 2014, compared to the first quarter of 2013. U.S. net Feraheme® (ferumoxytol) sales increased 12% to $17.4 million, compared to $15.6 million in the first quarter of 2013. AMAG ended the quarter with $385.5 million in cash and investments.
Help employers find you! Check out all the jobs and post your resume.
